Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches An Investigation Of Optimer Pharmaceuticals, Inc. Over The Proposed Sale Of The Company To Cubist Pharmaceuticals, Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Optimer Pharmaceuticals (“Optimer” or the “Company”) (NASDAQ GS: OPTR) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Cubist Pharmaceuticals, Inc. (NASDAQ GS: CBST) in a deal valued at approximately $801 million. Under the terms of the proposed transaction, Optimer’s stockholders will receive $10.75 in cash for each share of Optimer common stock they own. Optimer shareholders would also receive one Contingent Value Right for each Optimer share they own, which could yield additional cash consideration of up to $5.00 per share. According to Yahoo! Finance, at least one financial analyst has set a price target of $25.00 per share for Optimer.

Request more information now by clicking here: www.faruqilaw.com/OPTR . There is no cost or obligation to you.

The investigation focuses on whether Optimer’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of Optimer’s shareholders.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.

If you own common stock in Optimer and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/OPTR or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.

Copyright Business Wire 2010

If you liked this article you might like

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

Comcast, Cubist Jump Pre-market Amid Cautious Trading

Comcast, Cubist Jump Pre-market Amid Cautious Trading

Morning Briefing: 10 Things You Should Know

Morning Briefing: 10 Things You Should Know

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts